IGF-1 for nerve injuries research and science by Karim Sarhane today

Peripheral nerve regeneration studies with Karim Sarhane today? We performed a study with rodents and primates that showed this new delivery method provided steady release of IGF-1 at the target nerve for up to 6 weeks,” Dr. Karim Sarhane reported. Compared to animals without this hormone treatment, IGF-1 treated animals (rodents and primates) that were injected every 6 weeks showed a 30% increase in nerve recovery. This has the potential to be a very meaningful therapy for patients with nerve injuries. Not only do these results show increased nerve recovery but receiving a treatment every 6 weeks is much easier on a patient’s lifestyle than current available regiments that require daily treatment.

During his research time at Johns Hopkins, Dr. Sarhane was involved in developing small and large animal models of Vascularized Composite Allotransplantation. He was also instrumental in building The Peripheral Nerve Research Program of the department, which has been very productive since then. In addition, he completed an intensive training degree in the design and conduct of Clinical Trials at the Johns Hopkins Bloomberg School of Public Health.

Optimal dosage of IGF-1 is dependent upon its administration method. As demonstrated by Tables 1–6, there is great variation in IGF-1 dosing and frequency of administration between the various methods of delivery, with narrower ranges for ideal dosage that emerge within groups. These reported dosage ranges may serve as a useful reference point when developing and testing IGF-1 delivery strategies in pre-clinical models. Achieving the required pharmacokinetic profile for IGF-1 delivery is challenging due to the small size and short half-life of IGF-1. Therefore, designing drug delivery systems that provide targeted or local treatment of affected muscle and nerve tissue will facilitate clinical translatability of IGF-1 therapy. Local delivery of IGF-1 would reduce the side effects and potential toxicities of systemic exposure while permitting titration of loading levels to improve efficacy. However, the use of daily or frequent injections to an injury site, as described in previous studies, increases the risk of iatrogenic damage to the recovering nerve and surrounding vasculature (Caroni and Grandes, 1990; Day et al., 2001, 2002; Stitt et al., 2004; Emel et al., 2011; Mohammadi et al., 2013; Kostereva et al., 2016). In addition, the potential scarring induced by repeated local injections could preclude regenerating axons from reaching their distal targets, leading to decreased NMJ reinnervation as well as potential neuroma formation. Furthermore, the local injection of free IGF-1 without a biocompatible carrier misses an opportunity to improve its bioavailability. While the mini-pump technique provides a level of automated control over IGF-1 administration unmatched by the other previously described methods, the subcutaneous implantation of a mini-pump in a human patient introduces the risks of infection and device migration. More importantly, given the duration of time needed for regeneration to occur, the implanted pump would also likely induce a high degree of foreign body reaction resulting in fibrotic encapsulation and potential deleterious effects on the injured nerve being treated.

Recovery by sustained IGF-1 delivery (Karim Sarhane research) : Under optimized conditions, uniform PEG-b-PCL NPs were generated with an encapsulation efficiency of 88.4%, loading level of 14.2%, and a near-zero-order release of bioactive IGF-1 for more than 20 days in vitro. The effects of locally delivered IGF-1 NPs on denervated muscle and SCs were assessed in a rat median nerve transection-without- repair model. The effects of IGF-1 NPs on axonal regeneration, muscle atrophy, reinnervation, and recovery of motor function were assessed in a model in which chronic denervation is induced prior to nerve repair. IGF-1 NP treatment resulted in significantly greater recovery of forepaw grip strength, decreased denervation-induced muscle atrophy, decreased SC senescence, and improved neuromuscular reinnervation.

Following surgical repair, axons often must regenerate over long distances at a relatively slow rate of 1–3 mm/day to reach and reinnervate distal motor endplates. Throughout this process, denervated muscle undergoes irreversible loss of myofibrils and loss of neuromuscular junctions (NMJs), thereby resulting in progressive and permanent muscle atrophy. It is well known that the degree of muscle atrophy increases with the duration of denervation (Ishii et al., 1994). Chronically denervated SCs within the distal nerve are also subject to time-dependent senescence. Following injury, proliferating SCs initially maintain the basal lamina tubes through which regenerating axons travel. SCs also secrete numerous neurotrophic factors that stimulate and guide axonal regeneration. However, as time elapses without axonal interaction, SCs gradually lose the capacity to perform these important functions, and the distal regenerative pathway becomes inhospitable to recovering axons (Ishii et al., 1993; Glazner and Ishii, 1995; Grinsell and Keating, 2014).

Patients who sustain peripheral nerve injuries (PNIs) are often left with debilitating sensory and motor loss. Presently, there is a lack of clinically available therapeutics that can be given as an adjunct to surgical repair to enhance the regenerative process. Insulin-like growth factor-1 (IGF-1) represents a promising therapeutic target to meet this need, given its well-described trophic and anti-apoptotic effects on neurons, Schwann cells (SCs), and myocytes. Here, we review the literature regarding the therapeutic potential of IGF-1 in PNI. We appraised the literature for the various approaches of IGF-1 administration with the aim of identifying which are the most promising in offering a pathway toward clinical application. We also sought to determine the optimal reported dosage ranges for the various delivery approaches that have been investigated.